IMMX

Immix Biopharma Inc

8.06

Oct 26 • 3:59 PM ET -0.09 (-1.10%)

8.06

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: LEGN PRTA AUTL ALLO KYTX CABA FATE CRBU ALNY NKTX

| Held by: VTI XBI IWM VXF IWO VTWO DWAS VFMO IWC LABU

Scroll to Statements

Index	RUT
Market Cap	668.17M
Enterprise Value	437.06M
Income	-39.92M
Sales	0.00M
Book/sh	3.20
Cash/sh	2.80
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	21
IPO	Dec 16, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.52
P/C	2.88
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	25.13
Current Ratio	25.13
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.88
EPS next Y	-0.95
EPS next Q	-0.19
EPS this Y	18.96%
EPS next Y	-31.37%
EPS next 5Y	9.33%
EPS past 3/5Y	-12.81% -43.32%
Sales past 3/5Y	- -
EPS Y/Y TTM	-11.21%
Sales Y/Y TTM	-
EPS Q/Q	17.97%
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	-2.51% -

Insider Own	17.71%
Insider Trans	0.00%
Inst Own	67.68%
Inst Trans	60.95%
ROA	-31.34%
ROE	-34.18%
ROIC	-17.37%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-11.51%
SMA50	-29.14%
SMA200	-14.41%
Trades

Shs Outstand	71.54M
Shs Float	68.22M
Short Float	15.23%
Short Ratio	6.60
Short Interest	10.39M
52W High	15.10 -46.62%
52W Low	2.85 182.68%
Volatility	8.07% 7.69%
ATR (14)	0.67
RSI (14)	32.73
Beta	0.27
Rel Volume	0.71
Avg Volume	1.57M
Volume	1,116,282

Perf Week	-1.95%
Perf Month	-26.53%
Perf Quarter	-4.50%
Perf Half Y	-15.42%
Perf YTD	54.11%
Perf Year	123.27%
Perf 3Y	118.43%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	24.43
Prev Close	8.15
Price	8.06
Change %	-1.10%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-26	Initiated	Needham	Buy	$21
Jun-18-26	Initiated	BofA Securities	Buy	$27
Mar-25-26	Initiated	Morgan Stanley	Overweight	$20
Mar-09-26	Initiated	Citizens	Mkt Outperform	$23
Feb-09-26	Initiated	Mizuho	Outperform	$14

Oct-05-26 08:45AM	Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Sep-30-26 05:15PM	Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock (GlobeNewswire)
Sep-29-26 01:48PM	BofA Raises Odds Of Success For Immix Biopharmas NXC-201 Therapy Sees Over 190% Upside In IMMX Stock (Stocktwits) -8.11%
09:34AM	Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial (InvestorsHub)
07:05AM	Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock (GlobeNewswire)
07:00AM	Loading…
07:00AM	Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis (GlobeNewswire)
Aug-04-26 09:15AM	Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire) +10.81%
May-28-26 11:29AM	Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High? (Quartz)
May-22-26 05:15PM	Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock (GlobeNewswire)
May-21-26 06:30AM	Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock (GlobeNewswire)
06:00AM	Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 (GlobeNewswire)
Apr-09-26 08:45AM	Immix Biopharma to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) +11.43%
Mar-30-26 08:45AM	Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones (GlobeNewswire) +5.28%
Mar-03-26 08:45AM	Immix Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-28-26 08:45AM	Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 (GlobeNewswire)
10:48AM	Loading…
Jan-12-26 10:48AM	Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities (Benzinga) -8.83%
Dec-09-25 05:45PM	Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +7.32%
Dec-07-25 06:20PM	Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
06:15PM	At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis (GlobeNewswire)
Nov-12-25 08:45AM	Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch (GlobeNewswire) +15.17%
Nov-03-25 08:45AM	Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 (GlobeNewswire)
Oct-14-25 08:45AM	Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Oct-06-25 04:05PM	Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting (GlobeNewswire) +8.98% +11.80%
Oct-01-25 08:45AM	Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Sep-18-25 01:30PM	Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2 (GlobeNewswire) +6.63%
Sep-11-25 09:15AM	Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors (GlobeNewswire)
Sep-08-25 04:05PM	Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang (GlobeNewswire) +5.07%
Aug-25-25 09:30AM	Immix Biopharma to Present at the Stifel 2025 Healthcare Conference (GlobeNewswire)
Aug-06-25 12:30PM	Immix Biopharma Announces Other Serious Diseases Strategy (GlobeNewswire) -8.95%
Jul-11-25 09:36AM	Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion (GlobeNewswire)
09:35AM	Loading…
Jul-07-25 09:35AM	Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis (GlobeNewswire)
Jun-06-25 12:00PM	Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +8.22%
09:39AM	Immix Biopharma Attends FDA CEO Forum in Washington DC (GlobeNewswire)
Jun-03-25 02:55PM	Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis (GlobeNewswire) -18.85%
May-23-25 09:05AM	Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 (GlobeNewswire) -17.43%
May-22-25 04:02PM	Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis (GlobeNewswire) +15.31%
May-21-25 04:03PM	Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis (GlobeNewswire)
Apr-23-25 10:04AM	Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025 (GlobeNewswire)
Feb-10-25 09:35AM	Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis (GlobeNewswire)
Jan-07-25 09:34AM	Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T (GlobeNewswire)
Dec-19-24 09:35AM	Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis (GlobeNewswire) +5.71%
Dec-16-24 09:48AM	Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis (GlobeNewswire)
Dec-10-24 09:39AM	Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 (GlobeNewswire) -13.78%
Dec-09-24 09:33AM	Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media (GlobeNewswire)
Nov-25-24 09:32AM	Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients (GlobeNewswire)
Oct-02-24 09:32AM	Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 (GlobeNewswire)
Sep-19-24 09:31AM	Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board (GlobeNewswire)
Aug-28-24 09:32AM	Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 (GlobeNewswire)
Aug-19-24 12:00PM	What Makes Immix Biopharma (IMMX) a New Buy Stock (Zacks) +10.00%
Aug-12-24 10:52PM	IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024 (InvestorPlace) -5.13%
Jul-25-24 09:36PM	California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) (GlobeNewswire)
Jul-08-24 09:31AM	Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201 (GlobeNewswire) -8.47%
Jun-17-24 09:35AM	Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum (GlobeNewswire)
Jun-10-24 08:30AM	RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships (GlobeNewswire)
May-13-24 09:53AM	IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024 (InvestorPlace)
May-10-24 09:35AM	Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation (GlobeNewswire)
Apr-29-24 02:50PM	Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment (MT Newswires)
09:39AM	Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma (GlobeNewswire)
Apr-18-24 09:37AM	Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States (GlobeNewswire) -11.60%
09:32AM	Immix Biopharma on Track to Dose NXC-201 Patients in United States (GlobeNewswire)
Apr-15-24 09:36AM	Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
Apr-02-24 07:53AM	IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023 (InvestorPlace)
Mar-20-24 09:46AM	Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial (GlobeNewswire)
Mar-05-24 09:35AM	Immix Biopharma Announces Be Proactive in AL AL Amyloidosis Awareness Initiative (GlobeNewswire) -8.06%
Feb-21-24 09:31AM	Immix Biopharma 12 Month Review Progress Update (GlobeNewswire)
Feb-08-24 04:45PM	Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock (GlobeNewswire) +6.60%
Feb-07-24 09:37AM	Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis (GlobeNewswire) +7.07%
Feb-05-24 10:30PM	Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock (GlobeNewswire) -19.89% -6.29%
03:20PM	Immix Biopharma Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-24-24 08:35AM	Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products (GlobeNewswire)
Jan-04-24 09:34AM	Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board (GlobeNewswire)
Dec-18-23 09:39AM	Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board (GlobeNewswire) -8.94%
Dec-11-23 09:36AM	Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023 (GlobeNewswire)
Nov-30-23 09:46AM	Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-28-23 08:50AM	What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing' (Zacks) +5.39%
Nov-22-23 11:10AM	Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down (Zacks) +5.01%
09:19AM	Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis (GlobeNewswire)
Nov-21-23 09:46AM	Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing (GlobeNewswire)
Nov-06-23 09:18AM	Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients (GlobeNewswire) +20.73%
09:12AM	Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients (GlobeNewswire)
08:40AM	Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients (GlobeNewswire)
Oct-31-23 09:55AM	Here's Why Immix Biopharma, Inc. (IMMX) Is a Great 'Buy the Bottom' Stock Now (Zacks) +9.37%
Oct-26-23 08:58AM	Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board (GlobeNewswire)
Oct-16-23 09:05AM	Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire)
Oct-03-23 09:14AM	Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting (GlobeNewswire) +5.31%
Oct-02-23 08:06AM	Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma (GlobeNewswire) +26.61%
Sep-22-23 12:04PM	Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy (Zacks)
Sep-21-23 08:55AM	U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis (GlobeNewswire) +15.38%
Sep-19-23 09:10AM	Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire) +24.15%
Sep-15-23 01:18PM	Director Helen Adams Buys 13,000 Shares of Immix Biopharma Inc (IMMX) (GuruFocus.com) +5.12%
Sep-07-23 10:38AM	The 3 Best Speculative Stocks to Buy Now: September 2023 (InvestorPlace)
08:41AM	Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference (GlobeNewswire)
Sep-01-23 08:39AM	Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board (GlobeNewswire) +12.81%
Aug-23-23 08:37AM	U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma (GlobeNewswire) +11.11%
Aug-18-23 09:20AM	Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board (GlobeNewswire) +6.13%
Aug-16-23 09:05AM	Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece) (GlobeNewswire)
Jul-25-23 08:42AM	Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting (GlobeNewswire)
Jul-17-23 09:37AM	Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial (GlobeNewswire) -6.11%
Jul-10-23 09:47AM	Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire)
Jun-26-23 09:49AM	Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial (GlobeNewswire) -6.90%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rachman Ilya M	CEO and Chairman	Dec 10 '25	Buy	6.67	746	4,976	1,141,683	Dec 10 06:49 PM
Morris Gabriel S	CFO	Dec 10 '25	Buy	6.58	770	5,067	291,429	Dec 10 06:47 PM

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

M.D.Dr. Ilya Rachman M.B.A.

PresidentMr. Gabriel Morris B.A.

MSEDr. Vladimir P. Torchilin D.Sc.

M.D.Dr. Graham Ross FFPM

Ph.D.Dr. David Marks MBBS

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMMX

Immix Biopharma Inc

Upgrade your Finviz experience